Bangalore-based pharmaceutical company Strides Arcolab Ltd signed two licensing and supply agreements with Pfizer today.
In the first one, Strides would license and supply up to 38 generic oncology products to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan and Korea.
In the second, it is to commercialise sterile injectable products of Strides through its established products business unit. The company didn't disclose the financial terms of both agreements.
Strides had signed an earlier agreement with Pfizer, in January, to deliver 40 generic products, many of which are oncology therapeutics, to health care providers and patients in the United States. With these agreements, the collaboration between Pfizer and Strides would now extend to a total of 45 products, the company said in a filing today.
"It validates our strategic intent to be a partner to Pfizer, with a focus on specific therapeutic segments such as oncology," said Arun Kumar, vice-chairman and group CEO.
